On-chip study of the drug response of MCF-7 breast cancer tumour spheroids under chronic and cycling hypoxia

S. M. Grist, S. S. Nasseri, L. Laplatine, A. Díaz-Gaxiola, M. C. Liu, L. Chrostowski, K. C. Cheung*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

Abstract

We present a novel study of the response of MCF-7 tumour spheroids to the anticancer agent doxorubicin under normoxic as well as chronic and transient hypoxic conditions. Viability is monitored after a 72h treatment under 20% (normoxia), 1% (hypoxia), and 0.1% (anoxia) chronic O2 as well as under a cycling profile of 4h at 0% and 4h at 10% O2. We use a microfluidic oxygen control device to expose spheroids to varying O2 conditions and analyze their response with brightfield, widefield fluorescence, and two-photon microscopy (TPM), observing doxorubicin resistance in hypoxic spheroids.

Original languageEnglish (US)
Title of host publication20th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2016
PublisherChemical and Biological Microsystems Society
Pages403-404
Number of pages2
ISBN (Electronic)9780979806490
StatePublished - 2016
Event20th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2016 - Dublin, Ireland
Duration: Oct 9 2016Oct 13 2016

Publication series

Name20th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2016

Conference

Conference20th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2016
Country/TerritoryIreland
CityDublin
Period10/9/1610/13/16

Keywords

  • 3-D cell culture
  • Drug screening
  • Microfluidics
  • Transient/cycling hypoxia

ASJC Scopus subject areas

  • Control and Systems Engineering

Fingerprint

Dive into the research topics of 'On-chip study of the drug response of MCF-7 breast cancer tumour spheroids under chronic and cycling hypoxia'. Together they form a unique fingerprint.

Cite this